207 results about "Obesity prevention" patented technology

A device for controlling the expansion of a hollow internal organ, comprising an inflatable balloon, which is inserted in an uninflated state into the desired position close to the organ using minimally invasive procedures. After insertion, the balloon is inflated to its required size and shape. The invention is useful for restricting the expansion of the stomach during meals, thus inducing a feeling of satiety and preventing over-eating. Inflation may be performed through a catheter connected to a readily accessible inflation port. In the case of the gastric embodiment, the balloon may be positioned pro-peritoneally, such that the procedure is surgically simple. One or more sensors located close to the organ to be controlled, may monitor a physiological effect relating to the organ, and the output of the sensor used to control the level of inflation of the balloon in order to correct the condition being monitored.

Provided herein are methods and compositions for treating or preventing metabolic disorders, such as obesity and diabetes. Methods may comprise modulating the activity or level of a sirtuin, such as SIRTl or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin, or an inhibitory compound, such as nicotinamide.

A nutritional composition for controlling blood sugar level comprising a protein, a lipid and a carbohydrate, wherein energy percentages supplied by the protein, lipid and carbohydrate are 10 to 25%, 20 to 35% and 40 to 60%, respectively; and oleic acid in the lipid energy percentage is 60 to 90% and palatinose and/or trehalulose in the carbohydrate energy percentage is 60 to 100%. The composition is useful as an oral or tube feeding nutrient for nutritional management or blood sugar level control of patients suffering from diabetes and glucose intolerance, or for obesity prevention, a therapeutic diet, a diet for diabetic patients at home, an obesity preventive diet or a food with health claims.

The invention discloses a glucagon like peptide(GLP)-1 mutant polypeptide and a preparation method, a medicinal composition and use thereof. The mutant polypeptide is formed by bonding a Cys-containing elongation peptide to the N terminal of the glucagon like peptide-1 mutant, the mutant polypeptide itself folds to form a disulfide bond. The glucagon like peptide-1 mutant polypeptide is used for preparing a medicinal composition for treating diabetes and treating and preventing obesity. For overcoming the drawbacks of short retention time in body and need of daily injection administration of clinic GLP-1 analogue, the invention provides the GLP-1 analogue which has a longer half-life period. With the longer half-life period, the GLP-1 mutant polypeptide is not required to be injected into a patient every day, and can increase the obedience of the patient effectively.

The invention discloses a medicinal composition for treating or preventing the obesity and metabolic syndromes, and belongs to the medicine field. The medicinal composition treats orlistat and acarbose as medicinal active components, so the application amount of orlistat in the medicinal composition is substantially reduced, thereby the risk of the damage of orlistat to the liver of a body is reduced. The medicinal composition has a substantial synergistic effect when the medicinal composition is used for treating or preventing the obesity and the metabolic syndromes, can reduces the diabetes and angiocardiopathy suffering risks of obese patients, and has a wide medical application prospect.

A nasal device (10-16) for obesity prevention and treatment and its method of use are disclosed. The device comprises a check valve (20, 20′) and a cylindrical or conical airtight tube (30, 32′, 33, 34, 34′/36′) with an opening at each end. The valve is so fastened or connected to the tube at one end as to form a one-way air channel/passage. The tube conforms to or fits the interiors of different nostrils air-tightly in a variety of ways (32′, 34, 38, 40, 34′, 40′, 46). A pair of such devices can be connected with a flexible strip (42) or a band (44). Inserting the device into the nostril, a wearer can inhale through the nose but has to exhale through the mouth. This reduces the wearer's appetite for food and slows down eating. The wearer can easily remove the device after eating or whenever desired.

The invention discloses bifidobacterium animalis NX-6 and application thereof in preparation of lipid-lowering and weight-losing medicines, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium animalis NX-6 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 20114. The uninactivated and inactivated fermentation supernate, bacterial suspension and cell disrupted supernate of novel bifidobacterium animalis NX-6 show good effects of slowing down weight and body length increase, improving body mass index(BMI) and reducing fat area percentage on zebrafish, and have a potential weight losing effect; triglyceride (TG) and total cholesterol (TC) in a zebrafish hyperlipidemia model body can be obviously reduced, and a good hypolipidemic effect is shown. The novel bifidobacterium animalis NX-6 disclosed by the invention has a huge potential application prospect in the aspect of preparing medicines fortreating and/or preventing obesity and hyperlipidemia.

A combination chair and leg extension apparatus is provided. The apparatus uses a pneumatic source of resistence to provide a stowable flexor for the leg muscles which remains connected to the chair. Variations of the combination also provide for a combination desk, chair and leg extension apparatus, and a combination office chair and leg extension apparatus. The invention is to assist in prevention of obesity, particularly in children.

The invention relates to methods of treating or preventing obesity, type 2 diabetes, metabolic syndrome, or glucose intolerance using pyrido[3,2-e]pyrazines which are inhibitors of PDE10. The invention further relates to methods of reducing body fat or body weight.

Provided herein are methods and compositions for treating or preventing metabolic disorders, such as obesity and diabetes. Methods may comprise modulating the activity or level of a sirtuin, such as SIRTl or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin, or an inhibitory compound, such as nicotinamide.

The present invention relates generally to a new cluster of correlating molecules in a tissue or at least one cell of a tissue for instance a cell of a blood tissue, preferably such myeloid cells and of identifying the condition of the genes expression said correlating molecules or of the expression levels of said molecules in a method or system for identifying obesity and the risk at obesity-related metabolic diseases such as the obesity associated cardiovascular risk or obesity-related insulin resistance. This system of method provides information on how to modulate the correlating molecules to treat or prevent obesity and to prevent the obesity-related metabolic diseases.

The invention discloses a pure natural sweet potato beverage in original color and taste, which belongs to the field of food production process. The beverage is made from purple sweet potatoes as raw material, the process includes enzymolyzing purple sweet potato residue, preserving nutrients and color, flavoring, executing non-thermal sterilization treatment with a rare earth ultrasonic transducer, and packaging. According to the invention, the natural purple potato and the baking purple potato are used for providing natural flavor of the beverage, amylases and pectase are used to digest starch to provide a part of the sweet taste, and a large amount of nutrients such as antioxidants, multiple amino-acids or the like are preserved by maximum in the whole treatment process. The sweet red wine has bright color, fragrance special for purple sweet potato, slightly sweet taste, pure mouth feeling, long aftertaste, without sediment or cloudiness, which is suitable for long-term storage, and convenient for taking. The wine has functions of blood circulation promotion, fatigue recovering, obesity prevention and treatment, gastrointestinal function improvement, skin moistening or the like, is capable of suppressing generation of lipid peroxide, preventing human body aging, and has relative great cancer prevention effect.

A nutritive composite vitamine-trace element-white sugar necessary for normal energy metabolism for preventing and treating obesity, fatty liver, alcoholic liver, diabetes and hyperlipemia is prepared from VB1, VB2, VC, Se, Zn and white sugar. It can be used as food or food additive.

The invention relates to a health-care food containing natural fucoxanthin, which is a soft capsule. Moreover, an obesity preventing model method is adopted, and the fucoxanthin is used as a functional factor for carrying out a fat reducing experiment on a rat. By the display of data analysis, the weight and the perinephric spermary fat weight of the rat fed with the fucoxanthin are obviously lowered in comparison with those of a model set. Furthermore, the fat cell area is obviously reduced in comparison with that of the model set and a blank set. The result shows that the fucoxanthin has a very good fat reducing effect, and a favorable basis is provided to the application of substances containing the fucoxanthin in the field of health-care foods.

In general, this invention relates to nucleic acid and amino acid sequences involved in fat metabolism regulation and the use of these sequences as targets for the diagnosis, treatment, and prevention of obesity and obesity-related diseases. In addition, the invention relates to screening methods for identifying modulators of body fat metabolism and the development of treatments for obesity and obesity-related diseases.

The invention discloses the therapeutic and prophylactic administration of leptin to (i) an infant of low birth weight for age; (ii) a nursing mother of an infant, the infant having low birth weight for age; or (iii) a pregnant female predisposed to giving birth to an infant of low birth weight for age; for the prevention or treatment, in later life of the infant, of a metabolic disorder or other condition associated with low birth weight, such as type 2 diabetes, obesity, cardiovascular disease, gestational diabetes, impaired glucose tolerance, insulin resistance, hypertension or syndrome X. It is thought that the beneficial properties of leptin may be due at least in part to an effect on glucocorticoid metabolism, in particular to an increase in type 2 11β-hydroxysteroid dehydrogenase activity.

The present invention discloses applications of Bacteroides in treatment and prevention of obesity-related diseases, particularly applications of Bacteroides in preparation of a composition or preparation, wherein the composition or preparation is used for one or a variety of uses such as (A) prevention and/or treatment of obesity; (b) lowering of blood fat; (c) prevention or treatment of cardiovascular diseases; and/or (d) prevention and/or treatment of diabetes. The Bacteroides of the present invention can significantly reduce the body weight, the blood fat, and the body fat rate.

Embodiments of the invention disclose a Cordyceps-lucid ganoderma composition capable of improving immunity. The Cordyceps-lucid ganoderma composition comprises the following effective components in parts by weight: 6 to 15 parts of Cordyceps militaris powder, 8 to 20 parts of ginseng, 35 to 70 parts of Maca, 3 to 10 parts of astaxanthin, 30 to 60 parts of proanthocyanidins, 5 to 10 parts of lycopene, 35 to 70 parts of lucid ganoderma spore powder and 20 to 50 parts of vitamin E. Embodiments of the invention also disclose a preparation process for the above-mentioned Cordyceps-lucid ganodermacomposition capable of improving immunity. According to the invention, eight antioxidant substances--ginseng, Cordyceps militaris powder, Maca, astaxanthin, proanthocyanidin, lycopene, lucid ganodermaspore powder and vitamin E are combined in a certain proportion, so complementary and synergistic effects of the antioxidant substances are exerted; the effect of antioxidation is good; and a plurality of functions of preventing occurrence of a variety of tumors, preventing leukemia, exerting protection effects on eyesight and the central nervous system, preventing obesity and gout, reinforcing immunity, preventing cardiovascular diseases, preventing oxidation and aging, maintaining reproductive function and the like of a variety of substances can be simultaneously exerted.

The invention discloses an oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application and belongs to the field of medicine. The pharmaceutical composition comprises orlistat and lol-suffixed pharmaceutical active ingredients. The usage of orlistat and lol-suffixed pharmaceuticals in the pharmaceutical composition is greatly reduced, thus the risk of pharmaceuticals injuring the human body is reduced. The oral pharmaceutical composition has significant synergistic effect in treating or preventing obesity-related hypertension, can reduce the weight of a patient and the risk of hypertension being complicated by cardiovascular diseases and has higher social value.